Show Summary Details
Page of

The kidney in rheumatological disorders 

The kidney in rheumatological disorders
The kidney in rheumatological disorders

Wai Y. Tse

and Dwomoa Adu



Treatment of lupus nephritis—(1) recent publications show lower rates of renal flare in patients taking hydroxychloroquine; (2) in class V (membranous) disease ciclosporin and pulsed intravenous cyclophosphamide have both been shown to be better at inducing remission than prednisolone alone; other studies have shown that cyclophosphamide and mycophenolate mofetil are probably of equal efficacy; (3) 10-year follow up from the Euro-lupus trials shows that azathioprine is a very effective maintenance agent; (4) recent trials of biologic agents are discussed; many have not proved to be efficacious, but early results with the B-cell modulator belimumab (a human anti-BLyS antibody) show promise.

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 19 September 2021

Epidemiology and clinical features of renal disease—10 to 20% of patients with SLE have evidence of renal involvement at presentation, with this subsequently developing in about 40 to 50% of cases, typically during the first 5 years after diagnosis. Presentation is with proteinuria (causing nephrotic syndrome in ...

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.